Abstract
Purpose: The purpose of this study is to investigate the efficacy and safety of mirabegron versus solifenacin in the treatment of newly diagnosed overactive bladder (OAB) in children. Methods: We conducted a prospective randomized controlled study on pediatric patients with newly diagnosed OAB. Patients were randomized into 3 groups: mirabegron (50 mg once daily) in group I, solifenacin (5 mg) in group II, and placebo in group III. Before starting our treatment and at the end of the 3 months course, we obtained a 3-day voiding diary. This diary included incontinence episode per day, mean voided volume per micturition, mean number of micturition per day, and post-void residual urine. Moreover, the parents/patients were asked to rate symptom relief, and the adverse events were recorded throughout the study period. Results: A total of 190 patients aged from 5 to 14 years completed this study. At the end of this trial, both groups I and II showed significant improvement versus placebo regarding our efficacy parameters with no significant difference between group I and II. The overall success rate based on assessment of symptom relief was significantly higher in the treated groups (87.5% in I and 90.2% in II) versus placebo (55.8%). Dry mouth was reported in 2.8, 10, and 0% and constipation in 2.8, 11.4, and 1.4% in group I, II, and III, respectively, without statistically significant difference between group I and placebo. However, there was a significant difference between group II and placebo regarding these side effects. Conclusion: Both mirabegron and solifenacin have comparable efficacy regarding the control of OAB symptoms in the newly diagnosed children, but mirabegrone seems to have less side effects.
References
1.
Nadeau
G
, Schröder
A
, Moore
K
, Genois
L
, Lamontagne
P
, Hamel
M
, Long-term use of solifenacin in pediatric patients with overactive bladder: extension of a prospective open-label study
. Can Urol Assoc J
. 2014 Mar
;8
(3–4
):118
–23
. .2.
Andersson
KE
. Antimuscarinics for treatment of overactive bladder
. Lancet Neurol
. 2004 Jan
;3
(1
):46
–53
. .3.
Van Kerrebroeck
P
, Kreder
K
, Jonas
U
, Zinner
N
, Wein
A
, Tolterodine Study
G
. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder
. Urology
. 2001 Mar
;57
(3
):414
–21
. .4.
Madersbacher
H
. [Oral anticholinergics in overactive bladder]
. Urologe A
. 2006 Jul
;45
(7
):830
–4
. .5.
Alloussi
S
, Mürtz
G
, Braun
R
, Gerhardt
U
, Heinrich
M
, Hellmis
E
, Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: results of a multicentre observational cohort study
. BJU Int
. 2010 Aug
;106
(4
):550
–6
. .6.
Maman
K
, Aballea
S
, Nazir
J
, Desroziers
K
, Neine
ME
, Siddiqui
E
, Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison
. Eur Urol
. 2014 Apr
;65
(4
):755
–65
. .7.
Imran
M
, Najmi
AK
, Tabrez
S
. Mirabegron for overactive bladder: a novel, first-in-class beta3-agonist therapy
. Urol J
. 2013 Sep 26
;10
(3
):935
–40
.8.
Chapple
CR
, Kaplan
SA
, Mitcheson
D
, Klecka
J
, Cummings
J
, Drogendijk
T
, Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder
. Eur Urol
. 2013 Feb
;63
(2
):296
–305
.9.
Khullar
V
, Amarenco
G
, Angulo
JC
, Cambronero
J
, Hoye
K
, Milsom
I
, Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial
. Eur Urol
. 2013 Feb
;63
(2
):283
–95
.10.
Blais
AS
, Nadeau
G
, Moore
K
, Genois
L
, Bolduc
S
. Prospective pilot study of mirabegron in pediatric patients with overactive bladder
. Eur Urol
. 2016 Jul
;70
(1
):9
–13
. .11.
Morin
F
, Blais
AS
, Nadeau
G
, Moore
K
, Genois
L
, Bolduc
S
. Dual therapy for refractory overactive bladder in children: a prospective Open-Label Study
. J Urol
. 2017 Apr
;197
(4
):1158
–63
. .12.
Cardozo
L
, Thorpe
A
, Warner
J
, Sidhu
M
. The cost-effectiveness of solifenacin vs. fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health service
. BJU Int
. 2010 Aug
;106
(4
):506
–14
. .13.
Park
SJ
, Pai
KS
, Kim
JM
, Park
K
, Kim
KS
, Song
SH
, Efficacy and tolerability of anticholinergics in Korean children with overactive bladder: a multicenter retrospective study
. J Korean Med Sci
. 2014 Nov
;29
(11
):1550
–4
. .14.
Chapple
CR
, Rechberger
T
, Al-Shukri
S
, Meffan
P
, Everaert
K
, Huang
M
, Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder
. BJU Int
. 2004 Feb
;93
(3
):303
–10
. .15.
Newgreen
D
, Bosman
B
, Hollestein-Havelaar
A
, Dahler
E
, Besuyen
R
, Sawyer
W
, Solifenacin in children and adolescents with overactive bladder: results of a phase 3 randomised clinical trial
. Eur Urol
. 2017 Mar
;71
(3
):483
–90
. .16.
Hoebeke
P
, De Pooter
J
, De Caestecker
K
, Raes
A
, Dehoorne
J
, Van Laecke
E
, Solifenacin for therapy resistant overactive bladder
. J Urol
. 2009 Oct
;182
(4 Suppl
):2040
–4
. .17.
Newgreen
D
, Bosman
B
, Hollestein-Havelaar
A
, Dahler
E
, Besuyen
R
, Snijder
R
, Long-term safety and efficacy of solifenacin in children and adolescents with overactive bladder
. J Urol
. 2017 Oct
;198
(4
):928
–36
. .18.
Nitti
VW
, Auerbach
S
, Martin
N
, Calhoun
A
, Lee
M
, Herschorn
S
. Results of a randomized phase III trial of mirabegron in patients with overactive bladder
. J Urol
. 2013 Apr
;189
(4
):1388
–95
. .19.
Park
JS
, Lee
YS
, Lee
CN
, Kim
SH
, Kim
SW
, Han
SW
. Efficacy and safety of mirabegron, a beta3-adrenoceptor agonist, for treating neurogenic bladder in pediatric patients with spina bifida: a retrospective pilot study
. World J Urol
. 2019 Aug
;37
(8
):1665
–70
.20.
Fryer
S
, Nicoara
C
, Dobson
E
, Griffiths
M
, McAndrew
HF
, Kenny
SE
, Effectiveness and tolerability of mirabegron in children with overactive bladder: a retrospective pilot study
. J Pediatr Surg
. 2020 Feb
;55
(2
):316
–8
. .21.
Nitti
VW
, Khullar
V
, van Kerrebroeck
P
, Herschorn
S
, Cambronero
J
, Angulo
JC
, Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies
. Int J Clin Pract
. 2013 Jul
;67
(7
):619
–32
. .22.
Kelleher
C
, Hakimi
Z
, Zur
R
, Siddiqui
E
, Maman
K
, Aballéa
S
, Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis
. Eur Urol
. 2018 Sep
;74
(3
):324
–33
. .23.
Shamliyan
T
, Wyman
JF
, Ramakrishnan
R
, Sainfort
F
, Kane
RL
. Benefits and harms of pharmacologic treatment for urinary incontinence in women: a systematic review
. Ann Intern Med
. 2012 Jun 19
;156
(12
):861
–10
.24.
Yamaguchi
O
, Marui
E
, Kakizaki
H
, Homma
Y
, Igawa
Y
, Takeda
M
, Phase III, randomised, double-blind, placebo-controlled study of the β3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder
. BJU Int
. 2014 Jun
;113
(6
):951
–60
. .25.
Abrams
P
, Kelleher
C
, Staskin
D
, Rechberger
T
, Kay
R
, Martina
R
, Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony)
. Eur Urol
. 2015 Mar
;67
(3
):577
–88
. .26.
Ichihara
K
, Masumori
N
, Fukuta
F
, Tsukamoto
T
, Iwasawa
A
, Tanaka
Y
. A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction
. J Urol
. 2015 Mar
;193
(3
):921
–6
. .27.
Yamaguchi
O
, Kakizaki
H
, Homma
Y
, Igawa
Y
, Takeda
M
, Nishizawa
O
, Safety and efficacy of mirabegron as “add-on” therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study)
. BJU Int
. 2015 Oct
;116
(4
):612
–22
. .28.
Yamaguchi
O
. Antimuscarinics and overactive bladder: other mechanism of action
. Neurourol Urodyn
. 2010
;29
(1
):112
–5
. .© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
